Compare IDEXX Laboratories, Inc. (IDXX) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Tidewater Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Tidewater Inc trades at $85.42 (market cap $4.21B). The key difference: IDEXX Laboratories, Inc. is far larger — about 9.6× Tidewater Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Tidewater Inc for 26 Days on average.
| IDXX | TDW | |
|---|---|---|
Market Cap | $40.43B | $4.21B |
Volume | 692,164 | 590,005 |
Sector | Health | Energy |
52-Week High | $766.68 | $100.61 |
52-Week Low | $504.70 | $47.29 |
Typical Hold Time | 46 Days | 26 Days |
Enterprise Value | $41.32B | $4.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Tidewater (TDW) trades at $84.70, up 1.56% today, with a bullish technical signal from moving averages and a consensus analyst price target of $105.50. The company reported strong 2025 results with $1.35B revenue and $334.66M net income, though 2026 shows a decline. Recent news includes the completion of the Wilson Sons Ultratug acquisition and significant institutional buying by BlackRock.
The stock offers upside to the price target but faces risks from earnings volatility, as seen in recent quarterly misses, and exposure to energy market cycles. Investor sentiment is mixed with a majority hold rating from analysts, indicating cautious optimism amid operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
